0000000000083553

AUTHOR

Mercedes Vergara

showing 4 related works from this author

Outcome of liver cancer patients with SARS‐CoV‐2 infection: an international, multicentre, cohort study

2022

Background & Aims Information about the impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients with liver cancer is lacking. This study characterizes the outcomes and mortality risk in this population. Methods Multicentre retrospective, cross-sectional, international study of liver cancer patients with SARS-CoV-2 infection registered between February and December 2020. Clinical data at SARS-CoV-2 diagnosis and outcomes were registered. Results Two hundred fifty patients from 38 centres were included, 218 with hepatocellular carcinoma (HCC) and 32 with intrahepatic cholangiocarcinoma (iCCA). The median age was 66.5 and 64.5 years, and 84.9% and 21.9% had cirrhosis…

Settore MED/12 - GastroenterologiaCarcinoma HepatocellularHepatologyHepatocellular carcinomaSARS-CoV-2Liver NeoplasmsCOVID-19hepatocellular carcinomamortalityCohort Studiesliver cancerCOVID-19 TestingCross-Sectional Studiesmortality.HumansMortalityLiver cancerRetrospective Studies
researchProduct

Obeticholic Acid and Fibrates in Primary Biliary Cholangitis: Comparative Effects in a Multicentric Observational Study

2021

INTRODUCTION: Obeticholic acid (OCA) and fibrates therapy results in biochemical improvement in placebo-controlled trials in patients with primary biliary cholangitis and insufficient response to ursodeoxycholic acid. There is scarce information outside of clinical trials. Therefore, we have assessed the effectiveness and adverse events of these treatments. METHODS: Data from patients included in the ColHai registry treated with OCA, fibrates, or both were recorded during a year, as well as adverse events and treatment discontinuation. RESULTS: Eighty-six patients were treated with OCA, 250 with fibrates (81% bezafibrate; 19% fenofibrate), and 15 with OCA plus fibrates. OCA group had baseli…

Malemedicine.medical_specialtyPROGNOSISChenodeoxycholic AcidPLACEBO-CONTROLLED TRIALGastroenterology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineFenofibrateInternal medicinemedicineHumansBIOCHEMICAL RESPONSEAdverse effectCIRRHOSISRetrospective StudiesFenofibrateBezafibrateHepatologybusiness.industryLiver Cirrhosis BiliaryGastroenterologyObeticholic acidMiddle AgedBEZAFIBRATEUrsodeoxycholic acideye diseasesDiscontinuationURSODEOXYCHOLIC ACIDClinical trialTreatment Outcomechemistry030220 oncology & carcinogenesisAlkaline phosphatase030211 gastroenterology & hepatologyFemaleBezafibratebusinessmedicine.drug
researchProduct

Assessing the impact of COVID-19 on liver cancer management (CERO-19)

2021

[Background & Aims] The coronavirus disease 2019 (COVID-19) pandemic has posed unprecedented challenges to healthcare systems and it may have heavily impacted patients with liver cancer (LC). Herein, we evaluated whether the schedule of LC screening or procedures has been interrupted or delayed because of the COVID-19 pandemic.

Hepatocellular carcinomaLCmedicine.medical_treatment:diagnóstico::toma de decisiones clínicas [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS]NursesRC799-869Liver transplantationCholangiocarcinomaClinical trialsENS-CCAInterquartile rangeDecisió Presa dePandemic:Other subheadings::/diagnosis [Other subheadings]:virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES]CERO-19Pandèmia de COVID-19 2020-Immunology and AllergyiCCA intrahepatic cholangiocarcinomaCOVID-19 coronavirus disease 2019Liver Cancer Outcome in the COVID-19-pandemic ProjectSettore MED/12 - Gastroenterologiaddc:617IQRGastroenterologyBCLC Barcelona Clinic Liver Cancer:Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES]:neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias hepáticas [ENFERMEDADES]Diseases of the digestive system. GastroenterologyManagementClinical PracticeClinical trialEuropean Network for the Study of Cholangiocarcinoma:Diagnosis::Clinical Decision-Making [ANALYTICAL DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT]Fetge - Malalties - DiagnòsticInterquartile rangeLiver cancerLiver cancerPROGRESSION-FREE SURVIVALLiver Cancermedicine.medical_specialtyCoronavirus disease 2019 (COVID-19):Otros calificadores::/diagnóstico [Otros calificadores]610 Medicine & health:Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Liver Neoplasms [DISEASES]LT liver transplantationArticleBarcelona Clinic Liver CancerInternal MedicinemedicineENS-CCA European Network for the Study of CholangiocarcinomaHepatologybusiness.industryCERO-19 Liver Cancer Outcome in the COVID-19-pandemic ProjectCOVID-19IQR Interquartile rangemedicine.diseaseBCLCClinical trialEmergency medicineObservational study610 Medizin und GesundheitbusinessHCC hepatocellular carcinomaLC liver cancerSARS-CoV-2 severe acute respiratory syndrome coronavirus-2
researchProduct

International and multicenter real‐world study of sorafenib‐treated patients with hepatocellular carcinoma under dialysis

2020

Background & Aims: Information on safety and efficacy of systemic treatment in patients with hepatocellular carcinoma (HCC) under dialysis are limited due to patient exclusion from clinical trials. Thus, we aimed to evaluate the rate, prevalence, tolerability, and outcome of sorafenib in this population. Methods: We report a multicenter study comprising patients from Latin America and Europe. Patients treated with sorafenib were enrolled; demographics, dose modifications, adverse events (AEs), treatment duration, and outcome of patients undergoing dialysis were recorded. Results: As of March 2018, 6156 HCC patients were treated in 44 centres and 22 patients were concomitantly under dial…

NiacinamidesafetySorafenibdialysimedicine.medical_specialtyCarcinoma HepatocellularHepatocellular carcinomamedicine.medical_treatmentPopulationadverse eventAntineoplastic Agentssurvival03 medical and health sciences0302 clinical medicineRenal DialysisInterquartile rangeInternal medicineHepatocellular carcinoma; adverse events; dialysis; safety; sorafenib; survivalmedicineHumanseducationDialysisAgededucation.field_of_studyHepatologybusiness.industryPhenylurea CompoundsLiver NeoplasmsRetrospective cohort studyHepatitis CSorafenibmedicine.diseaseadverse eventsEuropeTreatment OutcomeTolerability030220 oncology & carcinogenesisHepatocellular carcinomadialysissorafenib030211 gastroenterology & hepatologybusinessmedicine.drugLiver International
researchProduct